



May 5, 2014

## Esperion Therapeutics to Provide First Quarter 2014 Financial Results

Conference Call and Webcast on Monday, May 12, 2014 at 4:30 p.m. Eastern Time

ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced that it will host a conference call and webcast to report first quarter 2014 operational and financial results. The webcast will take place on Monday, May 12, 2014 at 4:30 p.m. Eastern Time.

The call can be accessed by dialing (877) 312-7508 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing access code 29900745. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at [www.investor.esperion.com/events](http://www.investor.esperion.com/events). A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.

### About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently-available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit [www.esperion.com](http://www.esperion.com).

Media Contact:  
W2O Group  
Elliot Fox, 212.257.6724  
[efox@w2ogroup.com](mailto:efox@w2ogroup.com)

Source: Esperion Therapeutics, Inc.

News Provided by Acquire Media